Overview

Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND)

Status:
Completed
Trial end date:
2020-12-30
Target enrollment:
Participant gender:
Summary
Primary Objective: Assess the long term safety of sarilumab in patients with rheumatoid arthritis. Secondary Objective: Assess the long term efficacy of sarilumab in patients with rheumatoid arthritis.
Phase:
Phase 3
Details
Lead Sponsor:
Sanofi
Collaborator:
Regeneron Pharmaceuticals